Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 6/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2491947 | 0.94 | ZDHHC7 (0.42) | TSHRSMN1; SMN2CA2CA1ZDHHC7 | |
| SCHEMBL3184670 | 0.92 | ZDHHC7 (0.44) | CA2ZDHHC7FAAHCPB2 | |
| SCHEMBL6154829 | 0.92 | ZDHHC7 (0.44) | CA2ZDHHC7FAAHCPB2 | |
| SCHEMBL6155156 | 0.92 | ZDHHC7 (0.44) | CA2ZDHHC7FAAHCPB2 | |
| SCHEMBL1516015 | 0.88 | ALDH1A1 (0.39) | TSHRCTSKCYP3A4TDP1ALDH1A1 | |
| SCHEMBL7297863 | 0.86 | CA2 (0.42) | TSHRCA2CA1ATMCYP3A4 | |
| SCHEMBL7297867 | 0.86 | CA2 (0.42) | TSHRCA2CA1ATMCYP3A4 | |
| SCHEMBL9860634 | 0.84 | CA1 (0.55) | TSHRSMN1; SMN2CA2CA1CTSK | |
| SCHEMBL7909171 | 0.82 | TSHR (0.45) | TSHRCA2CA1ATMCYP3A4 | |
| SCHEMBL28944403 | 0.81 | CA2 (0.39) | TSHRCA2CA1ATMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1377266-A | Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion | MASSTRACE INC (CA) | 2002-10-30 | — | — | CN | claimed |
| US-7666659-B2 | Process for producing optically active 3-hydroxypropionic ester derivative | KANEKA CORPORATION (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20100016627-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-HYDROXYPROPIONIC ESTER DERIVATIVE | KANEKA CORPORATION (JP) | 2010-01-21 | — | — | US | disclosed |
| US-7323448-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323448-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| JP-2006280207-A | NEW CARBONYL REDUCTASE, GENE THEREOF AND METHOD FOR UTILIZING THE SAME | KANEKA CORP | 2006-10-19 | — | — | JP | disclosed |
| US-20060166342-A1 | Process for producing optically active 3-hydroxypropionic ester derivative | KANEKA CORPORATION (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1568679-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-HYDROXYPROPIONIC ESTER DERIVATIVE | KANEKA CORPORATION (JP) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005053610-A2 | DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| EP-0752989-B1 | THIAZOLYLPYRAZOLINONES AND THEIR USE FOR PROTECTING TECHNICAL MATERIALS | BAYER AG (DE) | 2000-07-19 | — | — | EP | disclosed |
| EP-0515934-B1 | Microbial application of 1-thiocarbamoyl-5-hydroxy-pyrazoles, 1-thiocarbamoyl-5-hydroxy pyrazoles and process for their fabrication | BAYER AG (DE) | 1998-09-09 | — | — | EP | disclosed |
| US-5703103-A | MICROBIOCIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1997-12-30 | — | — | US | disclosed |
| US-5672617-A | Medicaments containing 1-thiocarbamoyl-5-hydroxy-pyrazoles and their use as agents for combating septic shock | BAYER AKTIENGESELLSCHAFT (DE) | 1997-09-30 | — | — | US | disclosed |
| EP-0752989-A1 | THIAZOLYLPYRAZOLINONES AND THEIR USE FOR PROTECTING TECHNICAL MATERIALS | BAYER AG (DE) | 1997-01-15 | — | — | EP | disclosed |
| US-5510365-A | SUPPRESSION OF TUMOR NECROSIS FACTOR (TNFALPHA) ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 1996-04-23 | — | — | US | disclosed |
| US-5502069-A | FUNGICIDES IN PAINTS OR BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1996-03-26 | — | — | US | disclosed |
| WO-1995026962-A1 | THIAZOLYLPYRAZOLINONES AND THEIR USE FOR PROTECTING TECHNICAL MATERIALS | BAYER AKTIENGESELLSCHAFT (DE) | 1995-10-12 | — | — | WO | disclosed |
| EP-0638556-A1 | Medicaments containing 1-Thiocarbamoyl-5-hydroxy pyrazoles and their use as agents for the treatment of septic shock | BAYER AG (DE) | 1995-02-15 | — | — | EP | disclosed |
| EP-0515934-A1 | Microbial application of 1-thiocarbamoyl-5-hydroxy-pyrazoles, 1-thiocarbamoyl-5-hydroxy pyrazoles and process for their fabrication | BAYER AG (DE) | 1992-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016627-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3-HYDROXYPROPIONIC ESTER DERIVATIVE | HPD, GRHPR, PAH | TSHR 2517/4885SMN1; SMN2 4373/4885CA2 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.